Compare CDP & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | CRNX |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | 1996 | 2018 |
| Metric | CDP | CRNX |
|---|---|---|
| Price | $34.46 | $34.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $34.57 | ★ $76.75 |
| AVG Volume (30 Days) | 840.9K | ★ 884.6K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | ★ 8.94 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $763,923,000.00 | $1,039,000.00 |
| Revenue This Year | $1.18 | $720.10 |
| Revenue Next Year | $3.71 | $184.67 |
| P/E Ratio | $100.88 | ★ N/A |
| Revenue Growth | ★ 1.41 | N/A |
| 52 Week Low | $26.91 | $25.83 |
| 52 Week High | $34.78 | $57.99 |
| Indicator | CDP | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 73.02 | 47.34 |
| Support Level | $30.86 | $33.15 |
| Resistance Level | N/A | $37.23 |
| Average True Range (ATR) | 0.74 | 1.42 |
| MACD | 0.27 | 0.07 |
| Stochastic Oscillator | 89.74 | 52.19 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.